Form 4: Revolution Medicines' Chief Medical Officer Wei Lin Reports Stock Sale to Cover Taxes

Wei Lin, Chief Medical Officer of Revolution Medicines, sold 5,589 shares of common stock on June 17, 2024, to cover withholding taxes related to the vesting of restricted stock units.

Summary

• On June 17, 2024, Wei Lin, the Chief Medical Officer of Revolution Medicines, sold 5,589 shares of the company's common stock.
• The sale was executed to cover applicable withholding taxes associated with the vesting of restricted stock units (RSUs).
• The shares were sold at a weighted average price of $37.3867, with individual trades ranging from $37.3867 to $37.3871.
• Following the transaction, Wei Lin beneficially owns 70,851 shares, which includes 2,040 shares acquired through the Employee Stock Purchase Plan on May 31, 2024, and 59,250 RSUs.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock transactions by an officer, which is neither particularly positive nor negative.

Industry Context

Form 4 filings are a routine part of insider trading activity and are used by the SEC to ensure compliance with regulations.

Stakeholder Impact

• The sale of shares by a company officer could have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the reason for the sale.

Key Dates